NVP-BHG712 is primarily used in research settings as a selective inhibitor of the EphB4 receptor tyrosine kinase. It is employed to study signaling pathways involved in angiogenesis and tumor development, particularly in cancers where EphB4 and its ligand ephrin-B2 are overexpressed, such as in breast, ovarian, and prostate cancers. By blocking EphB4 activity, NVP-BHG712 helps researchers investigate the role of this receptor in tumor cell survival, migration, and vascular formation. It has also been used in preclinical models to assess the therapeutic potential of targeting the EphB4 pathway, supporting the development of new anticancer strategies. Its application remains confined to laboratory and experimental oncology research, with no current use in clinical therapy.